MARKET

IMCR

IMCR

Immunocore Holdings Plc
NASDAQ
61.54
-1.73
-2.73%
Closed 13:00 11/25 EST
OPEN
62.38
PREV CLOSE
63.27
HIGH
63.64
LOW
60.44
VOLUME
109.71K
TURNOVER
4.36M
52 WEEK HIGH
69.06
52 WEEK LOW
18.43
MARKET CAP
2.79B
P/E (TTM)
-24.2503
1D
5D
1M
3M
1Y
5Y
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%
The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that ...
Zacks · 4d ago
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the d...
GlobeNewswire · 4d ago
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday
Benzinga · 6d ago
HC Wainwright & Co. Maintains Buy on Immunocore Hldgs, Raises Price Target to $90
Benzinga · 6d ago
--HC Wainwright Ups Price Target on Immunocore Holdings to $90 From $80, Reiterates Buy Rating
--HC Wainwright Ups Price Target on Immunocore Holdings to $90 From $80, Reiterates Buy Rating
MT Newswires · 6d ago
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Benzinga · 11/18 19:03
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Zacks · 11/18 18:10
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Medpace (MEDP) have performed compared to their sector so far this year.
Zacks · 11/18 14:40
More
About IMCR
Immunocore Holdings plc, formerly Immunocore Holdings Ltd, is a late-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The Company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.

Webull offers kinds of Immunocore Holdings PLC - ADR stock information, including NASDAQ:IMCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMCR stock methods without spending real money on the virtual paper trading platform.